Abstract. It has been suggested that whey acidic protein (WAP) may function as a protease inhibitor. However, the actual function of WAP remains obscure. We investigated the histological development of the mammary glands of transgenic mice ubiquitously expressing WAP and CAG/WAP transgene. Ubiquitous expression of WAP induced aberrant development of the lobular alveoli of the mammary glands: mammary alveoli that were either aberrantly large or small in size increased in number in the developing mammary glands of these transgenic females during pregnancy and lactation. The expression of β-casein was precociously induced in the mammary glands of the transgenic females during early pregnancy and accompanying this was a histological observation that abnormally developed lobular alveoli filled with milk proteins appeared in the mammary glands of transgenic females during early pregnancy. However, during lactation, the development of mammary glands was impaired in transgenic females. To investigate the possible paracrine action of WAP associated with mammary gland aberration, we transplanted the mammary tissue of CAG/EGFP transgenic females into the fat pad of virgin CAG/WAP transgenic females and initiated pregnancy by mating. The development of mammary tissue transplanted to the recipient was histologically examined on day 3 of lactation. The results revealed that the development of grafted mammary tissues was impaired in a manner similar to that of the mammary glands of CAG/WAP transgenic females, indicating that the inhibitory effect of WAP acts via a paracrine mechanism. In vitro experiments using HC11 cells with forced expression of exogenous WAP demonstrated the inhibitory function of WAP on proliferation of mammary epithelial cells.
genes. β-casein is expressed during early pregnancy, while α-lactalbumin and whey acidic protein (WAP) are expressed around Days 13 and 14 of pregnancy, and these expressions are characterized by a terminal differentiation of the mammary secretory phenotype. WAP is a major whey protein found in the milk of rodents [4] [5] [6] [7] [8] , as well as in rabbit [9] , camel [10] , swine [11, 12] , wallaby [13] , and red kangaroo milk [14] . WAP proteins have a signal peptide and two domain structures that can be identified at the fourdisulfide core (4-DSC) [15] . Based on its sequence identity with known protease inhibitors, WAP likely functions as a protease inhibitor [5, 6, 11, 13, [15] [16] [17] [18] .
We have previously reported that WAP is expressed in various exocrine tissues other than the m a m m a r y g l a n d s i n l a c t a t i n g m i c e [ 1 9 ] . Furthermore, overexpression of the WAP transgene in the mammary glands of transgenic females resulted in poor development of the mammary glands [20] . It has also been reported that MMTV-LTR/WAP transgenic mice show hyperplasia of the coagulation gland epithelium, in addition to impaired mammary development [21] . Thus, such findings suggest that WAP plays some additional physiological role, not only in the mammary glands, but also in other tissues. To investigate the possible physiological functions of WAP, we previously generated transgenic mice ubiquitously expressing exogenous WAP under the control of the CAG promoter (CMV enhancer + β-actin promoter), and found only an aberration in mammary gland development [22] . However, in our previous study, the effects of ubiquitous expression of WAP on the mammary glands of the CAG/WAP transgenic females were not well characterized. Therefore, in this study, we focused on histological examination of the mammary glands of this transgenic mouse line during pregnancy and lactation. Herein, we report that the ubiquitous expression of WAP in the mammary glands induced the deregulated synthesis of β-casein, but impaired development of the mammary glands during lactation via a paracrine action of WAP.
Materials and Methods

Animals
Mice used throughout the present series of e x p e r i m e n t s w e r e k e p t u n d e r r e g u l a t e d temperature (22-25 C) , humidity (40-60%), and illumination cycles (14 h light, 10 h dark) conditions, and with food and water supplied ad libitum. The day when a vaginal plug was confirmed was designated as Day 1 of pregnancy, and the day of parturition was considered to be Day 1 of lactation. The pups were removed from their mother after 21 days of lactation, and that day was considered as Day 0 of mammary involution. The animal experiments were conducted in accordance with the guidelines for the care and use of laboratory animals of the School of Agriculture and Life Sciences at the University of Tokyo.
Transgenic mice
The CAG/WAP transgenic mouse line used in this study was from among the transgenic lines that h a v e b e e n p r o d u c e d i n o u r l a b o r a t o r y t o ubiquitously express WAP [22] . For transgene genotyping, genomic DNA was isolated from the tail and was analyzed by PCR. The following WAP-specific primers were used: forward primer, 5'-ATG-CGT-TGC-CTC-ATC-AGC-C-3'; and reverse primer, 5'-GAC-AGG-CAG-GGA-TGG-C-3'. PCR amplification was carried out by denaturing the DNA at 94 C for 1 min, followed by 25 cycles of amplification (at 94 C for 1 min), annealing (at 58 C for 1 min), and extension reactions (at 72 C for 1 min). At the end of the cycle, a final extension reaction was carried out at 72 C for 10 min. For the experiments involving the transplantation of mammary glands, CAG/EGFP transgenic mice that had been produced in our laboratory [23] were used as donors. Both the CAG/WAP transgenic mouse line and the CAG/ EGFP transgenic mouse line were bred in a C57BL6 genetic background. The expression of EGFP in CAG/EGFP transgenic mice was confirmed by visual green fluorescence under UV illumination. Wild-type littermates of CAG/WAP transgenic mice were used as the control.
Reverse transcription-PCR (RT-PCR)
RT-PCR primers specific for mouse WAP, α-lactalbumin, β-casein, WDNM I, and G3PDH cDNA sequences were designed using the Primer 3 software package (Invitrogen, Carlsbad, CA, U.S.A.). For the RT-PCR, the total RNA (1 µg) was denatured and reverse-transcribed into cDNA using SuperScrip II (Promega, Madison, WI, U.S.A.) in a reaction volume of 10 µl, according to the manufacturer's protocol. We used the following primer sequences for the amplification of transcripts from target genes: 5'-ATG-CGT-TGC-CTC-ATC-AGC-C-3' (forward) and 5'-GAC-AGG-CAG-GGAT-GGC-3' (reverse) for WAP; 5'-GTG-TAT-TTT-GTC-GTT-GCC-TGC-C-3' (forward) and 5'-TGT-AAA-ACC-CCC-ATC GAG-ACC-C-3' (reverse) for α-lactalbumin; 5'-CCT-CTC-TTG-TCC-TCC-ACT-AAA-G-3' and 5'-ACG-GAA-TGT-TGT-GGA-GTG-GCA-G-3' for β-casein; 5'-CCA-ACA-TGA-AGA-CAG-CCA-CAG-T-3' and 5'-AAG-CAT-GGG-GTC-TGT-AGG-TTC-A-3' for WDNM I; and 5'-TGA-AGG-TCG-GTG-TCA-ACG-GAT-TTG-GC-3' and 5'-CAT-GTA-GGC-CAT-G A G -G T C -C A C -C A C -3 ' f o r G 3 P D H ( a n endogenous control). All four deoxy A (d)-NTPs were included at a final concentration of 250 µM.
The PCR conditions were 24 cycles of 30 sec at 94 C, 30 sec at 58 C, and 1 min at 72 C. The PCR products were electrophoresed on a 1.2% agarose gel in TAE (Tris-acetate EDTA) buffer. For the quantitative analysis, the NIH Image software package (NIH, Bethesda, MD, U.S.A.; Version 1.60) was used; G3PDH cDNA products were used as the reference.
Immunoblotting
The mammary glands were isolated and homogenized in NP-40 lysis buffer (pH 8.0, 0.5% NP-40, 50 mM Tris-HCl, 200 mM NaCl, 20 mM NaF, 20 mM α-glycerophosphate, 0.1 mM Na 3 CO 4 , 1 mM dithiothreitol, 10 µg/ml leupeptin, 5 µg/ml aprotinin, and 1 mM PMSF) and were placed on ice for 15 min. Insoluble material was removed by centrifugation at 10,000 g for 5 min. The protein concentration was determined using a Bradford Assay Kit (Bio-Rad, Hercules, CA, U.S.A.). A onefifth volume of 5XSDS sample buffer was added to an aliquot of the supernatant containing 50 µg protein and was resolved on 15% reducing SDSpolyacrylamide gels, followed by electrophoretic transfer to PVDF membranes (Hybond; Amersham B i o s c i e n c e s , B u c k i n g h a m s h i r e , U K ) . T h e membranes were blocked for 30 min by soaking them in 3% defatted milk dissolved in PBS, and then they were incubated overnight at 4 C with the primary antibody dissolved in 3% defatted milk/ PBS. Anti-WAP antibody (goat polyclonal a n t i b o d y , M -1 6 : s c -1 4 8 3 2 ; S a n t a C r u z Biotechnology, Santa Cruz, CA, U.S.A.) was used at a 1/100 dilution, and anti-β-casein antibody (mouse monoclonal antibody, Biogenesis Ltd., Dorset, UK) was used at a 1/100 dilution. After being washed intensively in distilled water, the membranes were incubated for 90 min at room temperature with peroxidase-conjugated, affinity purified rabbit anti-goat IgG (H+L) for WAP or g o a t a n t i -m o u s e I g G + I g M ( J a c k s o n Immunoresearch Laboratories, West Grove, PA, U.S.A.) for β-casein, diluted 1/3000 in 3% defatted milk/PBS. After being washed in water, the membranes were developed by using an ECL Plus chemiluminescence detection kit (Amersham Biosciences, Buckinghamshire, UK), and the membranes were then exposed to X-ray film.
Histological examination of mammary glands
Female mice were sacrificed by cervical dislocation and the mammary tissues were removed. The tissues were fixed for 16 h in Bouin's solution, then rinsed in water and dehydrated using a graded alcohol series and xylene. The tissues were embedded in paraffin, sectioned at 6 µm, and stained with hematoxylin and eosin.
Morphometric analysis
To quantitatively evaluate the development of the mammary glands, morphometric analysis of the photomicrographs of sections of mammary alveoli sections was carried out using the Photoshop (version 5.0; Adobe, San Jose, CA, U.S.A.) and NIH Image software packages. The images of 150 to 500 mammary alveoli specimens were obtained from the sections of 3 independent glands for each mouse, and at least 3 mice were used for each experimental group.
Immunohistochemistry
The paraffin sections of the mammary glands were deparaffinized and hydrated using xylenes and a graded alcohol series, then rinsed in 3 changes of PBS for 5 min each. The sections were then blocked for 30 min at room temperature in 0.3% H 2 O 2 and methanol to quench endogenous peroxidase activity, and then were rinsed in 3 changes of fresh PBS for 5 min each. The sections were subsequently incubated with 5% rabbit whole serum (IBL, Shizuoka, Japan) in PBS for 30 min at room temperature, then rinsed in 3 changes of PBS for 5 min each to blot excess serum. The sections were then incubated with anti-WAP antibody dissolved in PBS containing 1% BSA at a 1/100 dilution, followed by incubation in the primary antibody for 16 h at 4 C. The sections were rinsed three times in fresh changes of PBS, then incubated for 30 min at room temperature with 1/200 diluted b i o t i n y l a t e d a n t i -g o a t I g G ( H + L ) ( V e c t o r Laboratories, Inc., Burlingame, CA, U.S.A.). After being washed in 3 changes of PBS for 5 min each, they were treated with Vectastain ABC Reagent (Vector Laboratories, Inc., Burlingame, CA, U.S.A.), a n d d e v e l o p e d u s i n g H i s t o f i n e ( N i c h i r e i Corporation., Tokyo, Japan). The sections were embedded on Micro Slide Glass (Matsunami Glass Ltd., Tokyo, Japan) with permount (Fairlawn, NJ, U.S.A.) after routine dehydration procedures.
Transplantation experiments
Transplantation was carried out as described by DeOme et al. [24] . Each mammary gland was surgically removed from the inguinal fat pad of 3-w e e k -o l d C A G / W A P t r a n s g e n i c f e m a l e s . Complete removal of the mammary gland was confirmed by whole mount staining of the enucleated mammary gland tissue in a preliminary e x p e r i m e n t .
E a c h f a t p a d m e a s u r i n g approximately 1.5 × 1.5 × 1.5 mm 3 in size was isolated from 7-8-week-old CAG/EGFP transgenic females and transplanted into the cleared inguinal fat pad of the CAG/WAP transgenic females. As a control, a portion (approximately 1.5 × 1.5 × 1.5 mm 3 ) of a mammary gland isolated from a CAG/ EGFP transgenic female was transplanted into the cleared inguinal fat pad of a 3-week-old wild-type female. Transplants were allowed to grow for 5 weeks after transplantation, and then the host mice were bred with males. The transplanted glands were harvested from the lactating females at 3, 7, and, 14 days of lactation, respectively. The removed transplants were examined for green fluorescence using a fluorescence microscope (BH-2; Olympus, Tokyo, Japan) and photographed. The tissues were fixed in Bouin's solution, and stained with Mayer's hematoxylin according to the whole mount protocol. The whole-mounted glands were d i r e c tl y i m a g e d w i th a s c a n n e r us i n g t h e Photoshop 5.0 software (Adobe, San Jose, CA, U.S.A.), and then the glands were embedded in paraffin, sectioned at 6 µm, and stained with hematoxylin and eosin for the morphometric analysis.
In vitro experiments
Cell culture and transfection of plasmids HC11 cells (kindly provided by Dr. R.K. Ball, Friedrich Miescher Institute, Switzerland) were grown in a complete medium, RPMI1640 (Gibco BRL, Gaithersburg, MD, U.S.A.), containing 10% (v/v) heat-inactivated FBS, 5 µg/ml of insulin, 10 ng/ml of epidermal growth factor, and 50 µg/ml of gentamicin. NIH3T3 cells (American Type Culture Collection, Manassas, VA, U.S.A.) from mouse fetal cells were used as a control for comparison with the HC11 cells and were grown in a complete medium, i.e., Dulbecco's Modified Eagle's Medium (Gibco BRL, Gaithersburg, MD, U.S.A.) containing 10% (v/v) heat-inactivated FBS, 100,000 U/l of penicillin, and 10 mg/l of streptomycin. The cells were cultured in a humidified atmosphere of 5% CO 2 in air at 37 C.
As an expression vector for transfection to the cells, the pCX-WAP plasmids and the pCX-EGFP plasmids as a control gene were used, respectively. The pCX plasmid contains an enhancer of the cytomegalovirus, chicken β-actin promoter with splicing sequences, and the rabbit β-globin 3'-flanking sequences [25] . The plasmids were transfected by the use of the Calcium Phosphate Profection Mammalian Transfection System (Promega, Madison, WI, U.S.A.) according to the manufacturer's instructions. For the establishment of stable plasmid expression, linearized plasmids were transfected into the cells and, after culturing the cells in complete medium for 2 days, cells demonstrating stable expression of plasmids were selected by passing the culture for 10 days in a complete medium containing G418 (700 µg/ml).
The EGFP stably transfected HC11 cells were used as control cells.
Assay of cell proliferation
Cell proliferation assay was done by the use of C e l l -C o u n t i n g K i t -8 s o l u t i o n ( W a k o P u r e Chemicals, Tokyo, Japan) [26] according to the manufacturer's instructions. The number of viable cells was measured at OD 450 nm using a Microplate Reader (Bio-Rad, Hercules, CA, U.S.A.).
Assay of apoptosis in the cells
Apoptosis in the WAP-clonal cells was analyzed according to a previously reported method [27] . There was no difference in the num ber of condensed or fragmented nuclei between WAPclonal HC11 cells and EGFP-clonal HC11 cells (control;data not shown).
Immunocytochemistry
The cells were fixed in 3% paraformaldehyde in PBS for 20 min, then in PBS or PBS containing 0.5% Triton X-100 for 15 min at 4 C. After being washed in PBS, the cells were blocked for 30 min in 8% skim milk in PBS, and then were incubated with the rabbit anti-mouse WAP antibody in a 1/100 dilution overnight at 4 C, followed by washing three times in PBS. For staining with PCNA, the cells were incubated in PBS containing PCNA antibody (Ab-1; Oncogene TM Research Products, Boston, MA, U.S.A.) in 1/400 dilution for 2 h at 37 C, followed by washing three times in PBS. The cells were incubated in PBS containing porcine antirabbit rhodamine-conjugated secondary antibody (1/100 dilution), and then were treated with FITCconjugated mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) for 1 h at 37 C. After washing 4 times in PBS, images were observed by confocal laser microscope (Carl Zeiss, Esslingen, Germany).
Statistical analysis
Data were analyzed by analysis of variance according to the Student's t-test. Differences between the mean values were considered to be statistically significant at p<0.05.
Results
WAP expression in the mammary glands of CAG/ WAP transgenic females
We initially examined the expression of WAP in the mammary glands of CAG/WAP transgenic mice at 12 different reproductive stages: 8-week-old virgin, pregnant (Days 4, 10, 14, 16, and 18 of pregnancy), lactating (Days 1, 3, 5, 7, and 14 of lactation), and mammary involuting stage (Day 2 of involution). We then compared the obtained values with the corresponding values observed in the mammary glands of wild-type females. Figure  1A shows the expression patterns of WAP transcripts in the mammary glands of wild-type and CAG/WAP transgenic females at 12 different reproductive stages. The WAP transcripts were detected in the mammary glands of transgenic females at the virgin stage; these transcripts are not typically detected in the mammary glands of wildtype females. The expression levels of WAP were almost always significantly higher in the mammary glands of the transgenic females than in those of the wild-type females at almost all of the reproductive stages, except for 2 days after weaning. However, the expression pattern of WAP was similar in wildtype and transgenic females during pregnancy and lactation. Immunoblot analysis demonstrated that WAP protein was produced in the mammary glands of the CAG/WAP transgenic females in the virgin stage and on Day 10 of pregnancy when WAP was not detected in the mammary glands of wild-type females (Fig. 1B) . 
Histological features of the mammary glands of CAG/ WAP transgenic mice
Wholemount specimens of the mammary gland showed impaired development of the lobular alveoli in CAG/WAP transgenic females in the l a c t a t i n g s t a g e ( d a t a n o t s h o w n ) . T h e immunohistological staining of WAP in the mammary glands of transgenic females was compared with the staining observed in the mammary glands of wild-type females in each equivalent stage (Fig. 2) . WAP protein was not detected in the mammary glands of the 8-week virgin wild-type mice (Fig. 2a) , whereas it was detected in various tissues other than the mammary glands of the CAG/WAP transgenic females (Fig. 2b) , i.e., in the lymph nodes and connective tissues (Fig. 2b) . No conspicuous histological difference was observed between the developing mammary glands of the transgenic females and the wild-type females in the virgin and early pregnancy stages (from Days 1 to 10 of pregnancy; data not shown). From day 16 of pregnancy onward, abnormally developed lobular alveoli filled with milk proteins appeared in the mammary glands of CAG/WAP transgenic females (Fig. 2d ). There were no lobular alveoli filled with milk protein in the mammary glands of wild-type females at this stage (Fig. 2c) . During lactation, it was observed that the number of lobular alveoli that were aberrantly large and that were filled with milk proteins had increased in the mammary glands of CAG/WAP transgenic females (Fig. 2f, h ), but a similar change was not observed in the mammary glands of wild-type females (Fig. 2e, g ). In addition, in the mammary glands of CAG/WAP transgenic females, the epithelial cells of large alveoli became thin, and the milk was stored in the lumens (Fig. 2f, h) .
Subsequently, to gain a better understanding of the appearance of abnormal lobular alveoli in the mammary glands of CAG/WAP transgenic females, we examined the distribution of alveoli of different sizes in the mammary glands, and we compared these findings with those obtained from the wild-type females. The results are shown in Fig. 3 . A significant increase in the number of abnormal lobular alveoli (in comparison with those of wild-type females) was seen in the mammary glands of CAG/WAP transgenic females on Day 3 of lactation (Fig. 3A) . The mammary fat pads were densely filled with uniformly sized mammary alveoli that ranged in cross-sectional size from approximately 1 × 10 -3 mm 2 to 2 × 10 -3 mm 2 . However, the lumen was frequently abnormally sized in the mammary glands of CAG/WAP transgenic females, as histologically shown in Fig.  2 . This tendency was observed in the transgenic females during lactation. In particular, on Day 14 of lactation, the number of abnormally large or small alveoli significantly increased in the transgenic mice; the variation in the size of alveoli was much greater in the CAG/WAP transgenic females than in the wild-type females on Day 14 of lactation. The range of sizes was ≤1 × 10 -3 mm 2 to ≥1 × 10 -2 mm 2 , and the relative frequency of alveoli sized 1 × 10 -3 mm 2 or smaller was four times as high as that in the wild-type control (Fig. 3B) .
Expression of milk protein genes other than WAP
We also investigated the expression patterns of milk protein genes other than the WAP gene, i.e., β-casein, α-lactalbumin, and WDNM I. The β-casein protein was expressed in CAG/WAP transgenic females earlier than in the wild-type mice during pregnancy (Fg. 4A). β-casein was precociously expressed in the CAG/WAP transgenic females on Day 4 and Day 10 of pregnancy, whereas it was not expressed or was very low in the wild-type females at the equivalent stage (Fig. 4B) . A significant excess of expression of the β-casein gene in the mammary glands of CAG/WAP transgenic females was not observed after late pregnancy and lactation (Fig. 4A) . The start of expression and the expression levels of α-lactalbumin and WDNM I did not differ between the transgenic females and the wild-type mice at any of the 12 different reproductive stages considered here (data not shown).
Outgrowth of grafted mammary glands
To investigate if the impaired development of the mammary glands of CAG/WAP transgenic females is caused by WAP via a paracrine mechanism, mammary tissue transplantation experiments were performed using CAG/WAP transgenic females and CAG/EGFP transgenic females, i.e., wild-type females for the WAP transgene.
First, in order to confirm whether or not grafted mammary tissues could develop normally, the mammary tissues from CAG/EGFP transgenic females were grafted to the cleared fat pads of wildtype females. The tissues from virgin CAG/EGFP transgenic donor females that were 7-8-week-old were transplanted to 3-week-old recipient animals. The grafted mammary tissues were collected from the recipients on Day 3 of lactation, and the fluorescence was observed under UV illumination (Fig. 5A) . Wholemount specimens were prepared in order to confirm whether or not the graft was successful, and then paraffin sections were prepared. We attempted to collect the grafted tissues from donor animals on Days 7 and 14 of lactation, but failed to recognize the fine structures of grafted tissue, as the relatively large amount of fat and the thickness of the grafted tissues disturbed the penetration of the UV rays. The grafted mammary tissues of CAG/EGFP transgenic females (wild-type females for the WAP transgene) were densely filled with uniformly sized mammary alveoli (Fig. 5B) . In contrast, poor alveolar development in the mammary glands of CAG/ EGFP transgenic females that had been grafted into the CAG/WAP transgenic females was observed, adipocytes were dominant in the grafted mammary gland on Day 3 of lactation, and only a small number of well-developed alveoli were observed, as shown in Fig. 5B .
Furthermore, we examined the distribution of The recipients were bred with males 5 weeks after transplantation, and the grafted tissues were harvested on day 3 of lactation. a, mammary tissue from a CAG/EGFP transgenic female transplanted into the fat pad of a wild-type recipient; b, mammary tissue of a CAG/EGFP transgenic female transplanted into the fat pad of a CAG/WAP transgenic recipient: many irregularly sized alveoli were seen. (C) Distribution of alveoli of different sizes in a cross-sectional area of the mammary glands of CAG/EGFP transgenic females that were transplanted to CAG/WAP transgenic females. Each point is the mean of the data from more than 3 animals. The area of 150 to 500 alveoli in 3 different cross-sectioned portions of the mammary gland was measured. The size of each alveolar was measured as described in "Materials and Methods". Wild-type recipient, a wild-type female recipient; WAP-Tg recipient, a CAG/WAP transgenic female recipient. *1, p<0.025; *2, p<0.005. different sized lobular alveoli in the grafted mammary tissues, and the results observed in different recipients were compared (Fig. 5C) . The diameter of the lobular alveoli of CAG/EGFP transgenic females that had been grafted to the wild-type females ranged from approximately 1 × 10 -3 mm 2 to 3 × 10 -3 mm 2 (cross-section), whereas the diameter of the lobular alveoli of the CAG/ EGFP transgenic females that had been grafted to the CAG/WAP transgenic females was aberrantly irregular, as seen in Fig. 3 .
Effects of forced expression of exogenous WAP on HC11 cells
We established 5 cloned HC11 cell lines stably expressing the exogenous WAP gene. We first investigated the effects of WAP expression on the proliferation of these WAP-clonal cells with various expression levels of exogenous WAP (Fig. 6A) . A 14-kDa WAP protein was detected in the medium where WAP clonal-cells were cultured, indicating that WAP was secreted into the medium (Fig. 6B) . In comparison with EGFP-clonal HC11 cells (#17, control), a significant inhibition of cell proliferation was observed in WAP-clonal HC11 cell lines with stable WAP expression, except one clone (#57), at 72 h after the start of culture (Fig. 6C) . This difference was not observed in the case of WAP-clonal NIH3T3 cells (data not shown). The results of double staining of the cells transiently expressing WAP with WAP-antibody and PCNA-antibody are shown in Fig. 6D . PCNA was detected in control HC11 cells without WAP expression (a, e, i), but not in those with WAP expression (b, f, j). In the case of NIH3T3 cells, PCNA was detected in both control cells (c, g, k) and WAP-expressing cells (d, h, i).
Discussion
Mammary gland development and the expression of milk protein genes in CAG/ WAP transgenic females
The present transgenic females had a number of abnormally developed large and/or small lobular alveoli with atypical milk proteins on Day 16 of pregnancy. Furthermore, the precocious and atypical expression of β-casein was also observed in the alveolar cells from the early to mid stage of pregnancy. The present results suggest that WAP may inhibit the proliferation of the mammary epithelium; however, this inhibition may induce the differentiation of mammary alveolar cells during pregnancy, resulting in the precocious expression of β-casein. WAP/WAP transgenic mice in which WAP is precociously synthesized have provided a model for the regulation of differentiation of mammary alveolar cells, whereby the precocious expression of WAP results in the terminal differentiation of alveolar cells already at mid-pregnancy, which in turn prevents the alveolar structures from proliferating [28] . Robinson et al. [28] also found that the altered expression of WAP in the mammary glands of WAP/WAP transgenic f e m a l e s i nd u c e d a s t r o n g r e d u c t i o n i n α -lactalbumin RNA. During pregnancy, the expression of individual milk protein genes varies greatly between neighboring cells within alveoli.
WDNMI and β-casein are expressed in early p r e g n a n c y a n d i n c r e a s e d u r i n g a l v e o l a r proliferation [28] . WAP and α-lactalbumin are expressed later, near the end of gestation. These observations suggest that the onset and progression of differentiation occurs asynchronously among cells.
Our results indicate that the early production of WAP in the mammary glands of CAG/WAP transgenic females induces the premature differentiation of mammary epithelial cells, leading to disruption in the timing of expression of the genes for milk protein, and in particular that of the gene for β-casein. However, the mechanism underlying the precocious expression of β-casein during early pregnancy in the mammary glands of CAG/WAP transgenic females remains unknown.
Transplantation experiments
In the mouse, the mammary epithelium grows out from the nipple into a fat pad that lies just under the skin. At three weeks after birth, the epithelium of these glands has not yet penetrated extensively into the stroma and can be eliminated by removing the nipple region of the mammary gland [24] . Mammary epithelial cells that are introduced into the remaining "cleared" fat pads will give rise to a new ductal system, and these cells can grow in such a manner that they can re-form a piece of breast tissue that is placed into the fat pad [24, 29] . This process allowed us to develop a procedure that would enable an investigation of the morphogenesis of the mammary tissues in an environment in which WAP is ubiquitously expressed around the transplant tissue in CAG/ WAP transgenic females. To confirm that the action of WAP, i.e., its inhibitory effect on the proliferation of the mammary epithelium, is a paracrine mechanism, we transplanted mammary tissues from CAG/EGFP transgenic females into CAG/WAP transgenic female recipients that were subsequently impregnated. We validated the success of this transplantation procedure by implanting mammary tissues of CAG/EGFP transgenic females into fat pads of wild-type females. The resulting engrafted glands developed in a manner similar to that of the endogenous mammary glands in virgin mice, as well as in postpartum recipients, demonstrating that the engrafted fat pad became fully vascularized when transplanted in this fashio n. The present transplantation experiments demonstrated that the development of lobular alveoli in grafted glands from CAG/EGFP transgenic donors was impaired in CAG/WAP transgenic recipients. This result was confirmed by the fact that the implants from CAG/WA P transgenic fe males showed an abnormal range of size among the lobular alveoli of CAG/WAP transgenic recipients. The variation in size of the implanted alveoli was much greater in the CAG/WAP transgenic recipients than in the wild-type recipients. The results of in vitro experiments supported the idea that WAP acts by a paracrine mechanism to inhibit proliferation of the mammary epithelium.
In vitro experiments
The results of in vitro experiments with cells of the mouse mammary epithelial line HC11 showed t h a t t h e p r o l i f e r a t i o n o f H C 1 1 c e l l s w a s significantly inhibited by forced expression of exogenous WAP, explaining well the aberrant small-sized alveoli that were observed in the mammary glands of CAG/WAP transgenic females. This inhibitory effect of WAP on cell p r o l i f e r a t i o n w a s a l s o d e m o n s t r a t e d b y immunocytochemical analysis; the expression of PCNA, a marker for cell proliferation, was inhibited in the HC11 cells that expressed exogenous WAP, but not in the NIH3T3 cells that showed WAP expression. On the other hand, as the expression of β-casein was precociously induced during pregnancy and was higher in the transgenic females, we attempted to confirm it in in vitro experiments using HC11 mouse mammary epithelial cells. However, the pr ecocious expression of β-casein in the mammary glands of the present CAG/WAP transgenic females was not confirmed by in vitro experiments (data not shown). Although the actual reason for this discrepancy remains unclear, it is suggested that multiple hormones other than the lactogenic hormones used for induction of differentiation of HC11 cells may be involved in the precocious and elevated expression of β-casein in the mammary glands of the transgenic females and in the difference between the WAP expression levels in vitro and in vivo.
In conclusion, the present results provide valuable insights into the function of WAP in the development of mammary glands. Proteases and protease inhibitors are thought to control tissue formation and remodeling during lobular alveolar development in the mammary glands [30] [31] [32] [33] . In a future studies, it will be necessary to investigate WAP function in terms of protease-protease inhibitor interactions in the mammary glands using both in vitro and in vivo systems.
